Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.

Abstract	Overexpression and activation of TPM3-ALK tyrosine kinase fusion protein is a causal oncogenic event in the development of Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic ALK-positive tumors. Thus, the development of ALK specific tyrosine kinase inhibitors is a current therapeutic challenge. Animal models are essential to assess, in vivo, the efficiency of ALK-oncogene inhibitors and to identify new and/or additional therapeutic targets in the ALK tumorigenesis pathway. Using the tetracycline system to allow conditional and concomitant TPM3-ALK and luciferase expression, we have developed a unique transplant model for bioluminescent TPM3-ALK-induced fibroblastic tumors in athymic nude mice. The reversible TPM3-ALK expression allowed us to demonstrate that this oncogene is essential for the tumor growth and its maintenance. In addition, we showed that this model could be used to precisely assess tumor growth inhibition upon ALK chemical inactivation. As proof of principle, we used the general tyrosine kinase inhibitor herbimycin A to inhibit ALK oncoprotein activity. As expected, herbimycin A treatment reduced tumor growth as assessed both by tumor volume measurement and bioluminescent imaging. We conclude that this transplant model for TPM3-ALK-induced tumors represents a valuable tool not only to accurately and rapidly evaluate in vivo ALK-targeted therapies but also to gain insight into the mechanism of ALK-positive tumor development.
Authors	Sylvie Giuriato, Nathalie Faumont, Emilie Bousquet, Marianne Foisseau, Anne Bibonne, Marc Moreau, Talal Al Saati, Dean W Felsher, Georges Delsol, Fabienne Meggetto
Journal	Cancer biology & therapy (Cancer Biol Ther) Vol. 6 Issue 8 Pg. 1318-23 (Aug 2007) ISSN: 1555-8576 [Electronic] United States
PMID	17660712 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antibiotics, Antineoplastic Benzoquinones Lactams, Macrocyclic Luminescent Agents Oncogene Proteins, Fusion Protein Kinase Inhibitors Tpm3 protein, mouse Tropomyosin Rifabutin herbimycin Luciferases Alk protein, mouse Anaplastic Lymphoma Kinase Protein-Tyrosine Kinases Receptor Protein-Tyrosine Kinases
Topics	Anaplastic Lymphoma Kinase Animals Antibiotics, Antineoplastic (pharmacology, therapeutic use) Benzoquinones (pharmacology) Cell Transformation, Neoplastic (genetics, metabolism) Disease Models, Animal Drug Screening Assays, Antitumor (methods) Genes, Reporter Lactams, Macrocyclic (pharmacology) Luciferases (analysis, genetics) Luminescent Agents (analysis) Lymphoma, Large-Cell, Anaplastic (drug therapy, enzymology) Mice Mice, Nude Neoplasm Transplantation Oncogene Proteins, Fusion (analysis, antagonists & inhibitors) Protein Kinase Inhibitors (pharmacology, therapeutic use) Protein-Tyrosine Kinases (analysis, antagonists & inhibitors) Receptor Protein-Tyrosine Kinases Rifabutin (analogs & derivatives) Tropomyosin (analysis, antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!